Aclarion (NASDAQ:ACON) Stock Rating Lowered by Wall Street Zen

Aclarion (NASDAQ:ACON) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Aclarion currently has an average rating of “Sell”.

Aclarion Price Performance

Shares of ACON stock opened at $3.27 on Friday. The firm has a market cap of $2.78 million, a PE ratio of -0.22 and a beta of 1.44. The company has a 50-day moving average of $3.57 and a two-hundred day moving average of $5.93. Aclarion has a 1-year low of $2.34 and a 1-year high of $48.33.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.